# Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

> **NCT01703702** · PHASE4 · COMPLETED · sponsor: **Avid Radiopharmaceuticals** · enrollment: 641 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** florbetapir (18F)

## Key facts

- **NCT ID:** NCT01703702
- **Lead sponsor:** Avid Radiopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2016-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703702, "Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01703702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*